| Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 82.19 mm | 82.19 mm | 82.19 mm | 82.19 mm | 82.19 mm | 82.19 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 13.30 mm | 10.81 mm | 9.88 mm | 8.33 mm |
| Cash used (since last report) | n/a | n/a | 30.54 mm | 24.83 mm | 22.69 mm | 19.14 mm |
| Cash remaining | n/a | n/a | 51.65 mm | 57.36 mm | 59.49 mm | 63.05 mm |
| Runway (months of cash) | n/a | n/a | 3.9 | 5.3 | 6.0 | 7.6 |
| 13F holders | Current |
|---|---|
| Total holders | 96 |
| Opened positions | 15 |
| Closed positions | 18 |
| Increased positions | 36 |
| Reduced positions | 20 |
| 13F shares | Current |
|---|---|
| Total value | 145.02 bn |
| Total shares | 54.20 mm |
| Total puts | 23.30 k |
| Total calls | 484.40 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| RARE Ultragenyx Pharmaceutical | 7.83 mm | $26.84 mm |
| Perceptive Advisors | 6.91 mm | $27.63 bn |
| Ra Capital Management | 4.33 mm | $17.32 bn |
| Bain Capital Life Sciences Investors | 4.03 mm | $16.14 bn |
| Siren, L.L.C. | 3.75 mm | $15.00 bn |
| Invus Global Management | 3.27 mm | $10.84 mm |
| Vestal Point Capital | 2.85 mm | $11.40 bn |
| Artal International S.C.A. | 2.72 mm | $20.93 mm |
| BCLS SB Investco | 2.30 mm | $18.55 mm |
| BlackRock | 1.86 mm | $7.44 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 19 Feb 25 | Perceptive Advisors | Common Stock | Buy | Acquire P | Yes | No | 4.03 | 5,000,000 | 20.15 mm | 11,833,539 |
| 19 Feb 25 | Ra Capital Management | Pre-Funded Warrants Common Stock | Buy | Acquire P | Yes | No | 4.029 | 3,722,085 | 15.00 mm | 3,722,085 |
| 19 Feb 25 | Bain Capital Life Sciences Investors | Common Stock | Buy | Acquire P | Yes | No | 4.03 | 1,000,000 | 4.03 mm | 5,034,582 |
| 19 Feb 25 | Bain Capital Life Sciences Investors | Pre-Funded Warrant Common Stock | Buy | Acquire P | Yes | No | 4.029 | 6,444,170 | 25.96 mm | 6,444,170 |
| 18 Feb 25 | Adage Capital Management | Common Stock, $0.001 par value per share | Buy | Acquire P | Yes | No | 7.56 | 252,545 | 1.91 mm | 4,248,084 |
